Effect of Bevacizumab Combined with Platinum-based Chemotherapy on Serum TGF-β1 and MIF Levels and the Prognosis of Patients with Advanced Ovarian Cancer
Objective To explore the effect of bevacizumab combined with platinum-based chemotherapy on serum transforming growth factor β1(TGF-β1)and macrophage migration inhibitory factor(MIF)levels and the prognosis of patients with advanced ovarian cancer.Methods A total of 68 patients with advanced ovarian cancer were selected,and divided into 2 groups according to the random number table method,with 34 patients in each group.The control group was treated with standard first-line chemotherapy(21 days as a cycle,6 cycles in total).The treatment group was treated with targeted drugs on the basis of chemotherapy.The standard first-line chemotherapy regimen was the same as that of the control group.After chemotherapy,the treatment group was treated with bevacizumab alone for 12 cycles.Therapeutic effect,TGF-β1 and MIF levels,adverse reactions,and the prognosis were compared between groups.Results There was no statistically significant difference in the objective remis-sion rate(ORR)between groups after treatment(P＞0.05).The disease control rate(DCR)in the treatment group was higher than that in the control group(P＜0.05).After treatment,TGF-β1 and MIF levels in the 2 groups decreased(P＜0.05),and the levels in treatment group were lower than those in the control group(P＜0.05).There was no statistically significant difference in the incidence rates of adverse reactions such as abdominal pain,diarrhea,nausea and vomiting,bone marrow suppression and di-gestive tract reactions between groups(P＞0.05).12 months of follow-up found that the recurrence and metastasis rate(23.55％)and mortality rate(8.82％)in the treatment group were significantly lower than those in the control group(47.06％and 29.41％)(x2=4.121,4.660,P=0.042,0.031).Conclusion Bevacizumab combined with platinum drugs can improve the clinical effect in the treatment of patients with advanced ovarian cancer and down-regulate the serum tumor markers(TGF-β1 and MIF)levels,without increasing adverse reactions and with good prognosis.
NETL
NSTL
万方数据
